The patent is rarely where the money is decided. The licence is. Three IP developments from the past week make that point, and each turns on terms settled, or left unsettled, long before anyone reached a court.
In the United Kingdom, the government has published its response to its consultation on standard essential patents, the patents behind 5G, Wi-Fi and similar standards. It has dropped the proposed rate-setting track and an official essentiality-checking service, and it will not restrict injunctions. What survives is work on an early, court-anchored FRAND determination, a possible IPO opinion service and good-faith negotiation guidance. For any business that builds on standards, the signal is plain. No regulator will set your royalty. The rate will be reached by negotiation, backed by a court, and the party with the better-documented conduct starts ahead. The UK courts were already the venue to watch, as Tesla’s FRAND appeal showed.
In Delaware, a jury found that Arm breached its architecture licence with Qualcomm and interfered with Qualcomm’s relationship with Meta, then awarded two dollars. The headline is not the number. The breach finding opens the question whether Qualcomm can suspend royalties for five years under a clause Arm says is unenforceable. The judge decides that next. One obligation about software patches and tools may move billions. A licence is a set of promises, each with a price attached, waiting for the day one is tested.
In pharmaceuticals, Liquidia agreed to pay United Therapeutics a net US$380.7 million after losing on one patent covering inhaled treprostinil for a single lung condition. It will not appeal, it is removing that indication from its label, and it has given covenants that run to 2042. Its shares rose about 40 per cent. The market paid for certainty, bought with structure: one indication surrendered, the larger PAH market kept, payments staged against sales. For the patent owner, one well-aimed claim on a specific use did the work of a portfolio.
What this means for your IP licensing strategy
Value sits in the terms, not the grant. Three checks follow.
– Read your licences for the clauses that would be litigated: what counts as breach, what happens to royalties when it occurs, and which fields are in and out.
– If you implement standards, document your negotiation conduct now. It is the record a court will read.
– Settle with structure. The question is not what you pay but what you keep, for how long and in which markets. Where Is Your Leverage? makes the same point from the enforcement side, and The Reverse Payment You Didn’t Know You Made shows what a badly structured settlement costs later.
An IP strategy that stops at the grant has done half the job. The other half is the deal that turns the right into revenue, or into a bill.
Read the sources: Government sets out next steps on standard essential patents, UK Intellectual Property Office; Delaware jury awards Qualcomm $2 in damages, finds Arm breached license agreement, CNBC; Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Liquidia Corporation.